新闻资讯

公司新闻

2024-10-25

领挚科技完成数千万元A轮融资,加速TFT生命科学产品交付及全球拓展。

2023-05-10

还有大动作!领挚科技投资新建TFT生物半导体研发中心

2023-05-08

「Avengers Assemble! 复仇者集结」——K神投身生物半导体革命

2023-02-21

恭喜杨一行博士晋升为联席CEO

2023-02-09

恭贺 | 领挚科技荣获国家【高新技术企业】认定

2022-12-31

这一年,【LinkZill·大事记】我们一起开启!

2022-09-05

领挚科技获数千万人民币Pre-A+轮融资,推进TFT半导体芯片在生命科学领域的应用落地

2022-07-11

恭贺 | 领挚科技在首届合成生物学竞赛创业赛,荣获融资组“SYNBIO FUTURE”金奖

2022-04-01

“挚盒01RC”巧遇伯乐“MIT南科望博士团队”——Nat. Bio. Eng. 报导便捷低成本的新型消化道测压仪!

2021-12-31

回顾 | 2021年大事记

2021-10-29

【36氪首发】领挚科技获数百万美金Pre-A轮融资,专注于TFT生物芯片(DNA合成,微流控,传感)产业化

2020-07-10

领挚科技完成天使轮融资

Dr. Kang Kang

Partner & CBio

Dr. Kang received his Ph.D. in Bioinformatics and Systems Biology from the University of Hong Kong in 2018, then became a scientific co-worker of the Leibniz Association (Leibniz-HKI) and a visiting scientist at the Novo Nordisk Foundation Center for Biosustainability (DTU Biosustain) at the Technical University of Denmark. He was a scientist at BGI-Shenzhen and co-founded the synthetic biology research group. He was a senior bioinformatics engineer and brand advisor at WeGene. In 2021, Kang joined Biosysen Limited as a co-founder and served as Chief Informatics Scientist. He is also an advisor and author of the biotech media "Regenesis". He has been dedicated to the R&D and industrialization of OMICs technologies, high-throughput technologies, and synthetic biology for over 10 years. He joined LinkZill in March 2023, responsible for semiconductor life science tools and product planning.